Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Currently, there is no single test for multiple sclerosis (MS). Diagnosis is confirmed through clinical evaluation, abnormalities revealed by magnetic resonance imaging (MRI), and analysis of cerebrospinal fluid (CSF) chemistry. The early and accurate diagnosis of the disease, monitoring of progression, and gauging of therapeutic intervention are important but elusive elements of patient care. Moreover, a deeper understanding of the disease pathology is needed, including discovery of accurate biomarkers for MS. Herein we review putative biomarkers of MS relating to neurodegeneration and contributions to neuropathology, with particular focus on autoimmunity. In addition, novel assessments of biomarkers not driven by hypotheses are discussed, featuring our application of advanced proteomics and metabolomics for comprehensive phenotyping of CSF and blood. This strategy allows comparison of component expression levels in CSF and serum between MS and control groups. Examination of these preliminary data suggests that several CSF proteins in MS are differentially expressed, and thus, represent putative biomarkers deserving of further evaluation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851054 | PMC |
| http://dx.doi.org/10.1155/2006/670439 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic pancreatic cancer biomarkers and pharmacogenetics.
Semin Cancer Biol
September 2025
Department of Oncology, Olomouc University Hospital, Olomouc, Czech Republic. Electronic address:
FOLFIRINOX and gemcitabine plus nab-paclitaxel represent the most effective chemotherapy regimens for metastatic pancreatic cancer patients nowadays, but the median overall survival remains less than one year. Pharmacogenomics and the individualization of therapy represent a promising strategy, including identifying patients at increased risk of toxicity. This review summarizes contemporary knowledge about genetic variability and putative biomarkers with published associations to therapy responses of pancreatic cancer not only for gold standard treatment regimens (FOLFIRINOX, gemcitabine/nab-paclitaxel and nal-IRI/5-fluorouracil) but also for other therapeutic options regarding targeted therapy and immunotherapy.
View Article and Find Full Text PDFDihydromyricetin attenuates age-related macular degeneration: pharmacological effects and exploration of putative targets.
Front Pharmacol
August 2025
College of Pharmacy, Binzhou Medical University, Binzhou, Shandong, China.
Introduction: Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, with limited effective treatments available. This study aimed to investigate the pharmacological effects of dihydromyricetin (DHM) on AMD and to identify its putative pharmacological targets through network analysis and molecular docking approaches.
Methods: experiments established an AMD model using sodium iodate (SI)-induced ARPE-19 cells, with CCK-8 assays determining 15 mM SI as the optimal modeling concentration and 100 μM DHM as the optimal treatment concentration.
Expressed mutated genes in Sezary syndrome and their potential prognostic value in patients treated with extracorporeal photopheresis.
Front Immunol
September 2025
Laboratory of Molecular Oncology, Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy.
Background: Sézary syndrome (SS) is an aggressive and leukemic variant of Cutaneous T-cell Lymphoma (CTCL) with an incidence of 1 case per million people per year. It is characterized by a complex and heterogeneous profile of genetic alteration ns that has so far precluded the development of a specific and definitive therapeutic intervention.
Methods: Deep-RNA-sequencing (RNA-seq) data were used to analyze the single nucleotide variants (SNVs) carried by 128 putative CTCL-driver genes, previously identified as mutated in genomic studies, in longitudinal SS samples collected from 17 patients subjected to extracorporeal photopheresis (ECP) with Interferon-α.
Lipidomic Signature of Abdominal Aortic Aneurysm and Peripheral Artery Disease.
J Proteome Res
September 2025
UnIC@RISE Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, 4200-319 Porto, Portugal.
Vascular diseases are powerful predictors of cardiovascular mortality, but they are typically under-recognized and undertreated. There is no effective treatment for either abdominal aortic aneurysm (AAA) or peripheral artery disease (PAD). Lipids are key molecules in cardiovascular diseases and good candidates for diagnosis, monitoring, and risk prediction; nonetheless, there is very limited information on the lipidomic profile of patients with AAA and PAD.
View Article and Find Full Text PDFDiagnosing pulmonary tuberculosis (PTB) remains challenging, particularly in people living with HIV (PLWH) who have a high rate of false-negative tests using expectorated sputum. Urine, a non-invasive sample, offers a valuable source of metabolites reflecting systemic changes in disease. This study utilized liquid chromatography-mass spectrometry to investigate urinary biomarkers previously identified in other cohorts, using a well-characterized population of people newly-diagnosed with HIV who screened positive for TB symptoms in Port-au-Prince, Haiti.
View Article and Find Full Text PDF